Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

143.14USD
24 Mar 2017
Change (% chg)

$0.64 (+0.45%)
Prev Close
$142.50
Open
$142.45
Day's High
$144.56
Day's Low
$141.94
Volume
166,166
Avg. Vol
202,699
52-wk High
$160.00
52-wk Low
$95.80

Latest Key Developments (Source: Significant Developments)

Jazz Pharmaceuticals Q4 adj earnings per share $2.71
Tuesday, 28 Feb 2017 04:05pm EST 

Jazz Pharmaceuticals Plc : Jazz Pharmaceuticals Plc sees 2017 revenues $1,625-$1,700 million . Jazz Pharmaceuticals Plc sees 2017 total net product sales $1,617-$1,692 million . Jazz Pharmaceuticals Plc sees 2017 GAAP net income per diluted share $6.55-$7.55 . Jazz Pharmaceuticals Plc sees 2017 NON-GAAP adjusted net income per diluted share $10.70-$11.30 . FY2017 earnings per share view $11.33, revenue view $1.68 billion -- Thomson Reuters I/B/E/S . Jazz pharmaceuticals announces full year and fourth quarter 2016 financial results . Q4 adjusted earnings per share $2.71 . Q4 GAAP earnings per share $1.91 .Q4 earnings per share view $2.65 -- Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease
Wednesday, 8 Feb 2017 04:05pm EST 

Jazz Pharmaceuticals Plc : Jazz Pharmaceuticals announces first patient enrolled in Phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease .Jazz Pharmaceuticals Plc- Study is expected to enroll approximately 50 patients for phase 2 clinical study evaluating JZP-110.  Full Article

Jazz Pharmaceuticals comments on FDA nod for generic version of Xyrem
Wednesday, 18 Jan 2017 06:24am EST 

Jazz Pharmaceuticals Plc : Jazz Pharmaceuticals says it will evaluate FDA's waiver of requirement for a single, shared system rems in connection with approval of a generic version of Xyrem . Says it will evaluate whether FDA's waiver meets conditions for such a waiver under applicable law .Says it intends to evaluate potential challenges to FDA's waiver decision on the generic version of Xyrem.  Full Article

Jazz Pharma Q2 adjusted earnings per share $2.63
Tuesday, 9 Aug 2016 04:05pm EDT 

Jazz Pharmaceuticals Plc : Jazz pharmaceuticals announces second quarter 2016 financial results . Q2 gaap earnings per share $1.80 . Updated financial guidance for 2016. . Q2 adjusted earnings per share $2.63 . Q2 earnings per share view $2.80 -- Thomson Reuters I/B/E/S . Sees 2016 gaap net income per diluted share $5.66-$6.56 . Fy2016 earnings per share view $11.14, revenue view $1.52 billion -- Thomson Reuters I/B/E/S . Q2 revenue view $376.4 million -- Thomson Reuters I/B/E/S . Qtrly total revenues $381.2 million versus $333.7 million . Sees 2016 revenue $1,485 million to $1,530 million .Sees 2016 non-gaap adjusted net income per diluted share $9.90-$10.30.  Full Article

Jazz Pharmaceuticals and Pfenex enter into an agreement
Thursday, 28 Jul 2016 04:05pm EDT 

Pfenex Inc : Under agreement, Pfenex will receive upfront and option payments totaling $15 million . Co may be eligible to receive additional payments of up to $166 million based on achievement of certain development milestones . Pfenex may also be eligible to receive tiered royalties on worldwide sales of any products resulting from collaboration .Jazz Pharmaceuticals and Pfenex enter into a worldwide license and option agreement related to product candidates in early development for Hematological Malignancies.  Full Article

S&P-Jazz Pharmaceuticals Plc ratings affirmed on Celator acquisition plan outlook stable
Tuesday, 31 May 2016 06:04pm EDT 

S&P : Stable rating outlook reflects expectation that leverage will remain comfortably below 3x . Jazz pharmaceuticals plc ratings affirmed on Celator acquisition plan; outlook stable . Do not expect Celator to contribute meaningful sales and cash flows until 2018 Source (http://bit.ly/1TIwM22) Further company coverage: [JAZZ.O,CPXX.O] (Bengaluru Newsroom) (((+91 80 6749-1130; within U.S. +1 646 223 8780);)).  Full Article

Jazz Pharmaceuticals Q1 gaap earnings per share $1.19
Tuesday, 10 May 2016 05:00pm EDT 

Jazz Pharmaceuticals Plc : Sees 2016 revenues $1,490 million -$1,550 million . Sees 2016 gaap net income per diluted share $6.76-$7.41 . Sees 2016 non-gaap adjusted net income per diluted share $11.10-$11.50 . Sees 2016 total net product sales $1,482 million -$1,542 million . Sees 2016 adjusted gross margin 93% . Fy2016 earnings per share view $11.14, revenue view $1.53 billion -- Thomson Reuters I/B/E/S . Jazz pharmaceuticals announces first quarter 2016 financial results . Q1 adjusted earnings per share $2.26 . Q1 gaap earnings per share $1.19 . Q1 earnings per share view $2.31 -- Thomson Reuters I/B/E/S .Q1 revenue $336 million versus i/b/e/s view $338.9 million.  Full Article

Jazz Pharmaceuticals PLC announces FDA approval of Defitelio for treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation
Wednesday, 30 Mar 2016 02:32pm EDT 

Jazz Pharmaceuticals PLC:Says FDA granted marketing approval for Defitelio for treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following HSCT.  Full Article

Jazz Pharmaceuticals PLC gives FY 2016 guidance
Tuesday, 23 Feb 2016 04:05pm EST 

Jazz Pharmaceuticals PLC:Sees FY 2016 Revenues $1,490-$1,550 million.Sees FY 2016 Total net product sales $1,482-$1,542 million.Sees FY 2016 GAAP net income per diluted share $6.76-$7.41.Sees FY 2016 Non-GAAP adjusted net income per diluted share $10.90-$11.30.  Full Article

Jazz Pharmaceuticals PLC narrows FY 2015 guidance
Monday, 9 Nov 2015 04:05pm EST 

Jazz Pharmaceuticals PLC:Expects FY 2015 revenues of $1.320-$1.340 billion.Expects FY 2015 GAAP net income per diluted share of $5.42-$5.63.Expects FY 2015 Non-GAAP adjusted net income per diluted share of $9.45-$9.60.FY 2015 revenue of $1.35 billion and EPS of $9.67 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Jazz Pharmaceuticals announces positive results from phase 3 tones 3 and tones 4 studies of JZP-110

* Jazz pharmaceuticals announces positive results from the phase 3 tones 3 and tones 4 studies of jzp-110 in patients with obstructive sleep apnea Source text for Eikon: Further company coverage: